Infliximab biosimilar - Merck & Co./Samsung Bioepis
At a glance
- Drug Originator Samsung Bioepis
- Drug Licenced by Biogen; Ewopharma; Merck & Co
- Drug Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
- USA Patent Applicants SAMSUNG BIOEPIS CO LTD
- USA Patents 1
- BLAs 1
Table of Contents

Disclaimer